Products with Antihyperglycemic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2931 | Semilicoisoflavone B |
| 1. Semilicoisoflavone B can inhibit sorbitol formation of rat lens incubated with a high concentration of glucose, indicates that it may be effective for preventing osmotic stress in hyperglycemia. | |
| BCN2948 | Fucoxanthin |
| Fucoxanthin shows anti-obesity, antioxidant, anti-inflammatory, chemopreventive and/or chemotherapeutic effects. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. Fucoxanthin suppresses the inflammation of endotoxin-induced uveitis by blocking the iNOS and COX-2 protein expression and its anti-inflammatory effect on eye is comparable with the effect of predinisolone used in similar doses. | |
| BCN2954 | Desoxyrhaponticin |
| Desoxyrhaponticin is an agent that is potentially effective in controlling postprandial hyperglycemia in diabetes. Desoxyrhaponticin could be considered as a promising fatty acid synthase(FAS) inhibitor, it could inhibit intracellular FAS activity and downregulate FAS expression in human breast cancer MCF-7 cells. | |
| BCN2982 | Kushenol A |
| Kushenol A is a kind of Adenosine 3', 5'-cyclic monophosphate(cAMP)phosphodiesterase inhibitiors, it shows selective alpha-glucosidase inhibitory activity. Kushenol A and kushenol C exhibit inhibitory activity against Sodium-dependent glucose cotransporter 2(SGLT2). | |
| BCN3174 | Mahanimbine |
| 1. Mahanimbine inhibits AChE activity in a dose-dependent manner. 2. Mahanimbine and mangiferin increases the glucose utilization in a dose-dependent manner, can prevent obesity and use in management of diabetes. 3. Mahanimbine can prevent high-fat diet (HFD)-induced hyperlipidemia and fat accumulation in adipose tissue and liver along with the restricted progression of systemic inflammation and oxidative stress. 4. Mahanimbine can lower the absorption of dietary fat resulting in dietary fat excretion. | |
